Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin c + epirubicin + cisplatin
- Development stage
- Preclinical
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of **mitomycin C**, **epirubicin**, and **cisplatin**, each of which belongs to a different class of antineoplastic agents. Mitomycin C is an alkylating agent with DNA cross-linking activity, epirubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, and cisplatin is a platinum-based compound that causes DNA cross-linking and apoptosis. This combination is designed for synergistic anti-tumor effects and is primarily investigated for treatment of various solid tumors, though there are no established standard protocols for this exact combination.
- Other names
- MEPMEP regimenmitomycin C + epirubicin + cisplatinmitomycin C, epirubicin, and cisplatinmitomycin-C + epirubicin + cisplatin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitomycin c + epirubicin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin c + epirubicin + cisplatin.